The treatment and management of COVID-19 patients is evolving rapidly. There is a global effort to discover novel treatments and test existing therapies that are safe and effective.

To date, the FDA has only granted a few Emergency Use Authorizations (EUA) for COVID-19 related treatments including: Remdesivir from Gilead Sciences (NASDAQ – GILD), convalescent plasma and gammaCore SapphireTM CV from electroCore, Inc. (NASDAQ – ECOR). More innovation is needed faster.

David Shulkin, MD, 9th Secretary of Veterans Affairs, will moderate a 45 minute Essential Conversation on COVID-19 therapeutics and management of the virus with patients at home and in the hospital with medical leaders on the front line of the fight against COVID-19. Q&A with participants will follow.

Date: October 28 at 11:00 am ET

Join us. Free Registration:

Faculty:
• Sten Lindahl, MD, PhD, FRCA. Chair Emeritus of the Nobel Committee in Physiology of Medicine; Professor Emeritus, Karolinska Institute, Stockholm, Sweden
• Paul Currier, MD, MPH Director of the Respiratory Care Unit and the Director of Quality for the Division of Pulmonary and Critical Care at Massachusetts General Hospital
• Peter Staats, MD, Chief Medical Officer for National Spine and Pain Centers and Chief Medical Officer, electroCore, Inc.
• Jennifer Pena, MD, Medical Director for Global Executive Medicine, Executive Medicine Physician at Inova Health System VIP 360, and former Physician to Vice President of the United States

Important Safety Information for gammaCore Sapphire (nVNS):
• Headache: Instructions for Use and Important Safety Information
• EUA: Instructions for Use and Important Safety Information

• Additional EUA information:
• Authorization Letter: https://www.fda.gov/media/139967/download

• Fact Sheet for HCPs: https://www.fda.gov/media/139968/download

• Fact Sheet for Patients: https://www.fda.gov